181 related articles for article (PubMed ID: 18714186)
1. Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
Herszényi L; István G; Cardin R; De Paoli M; Plebani M; Tulassay Z; Farinati F
Eur J Cancer Prev; 2008 Oct; 17(5):438-45. PubMed ID: 18714186
[TBL] [Abstract][Full Text] [Related]
2. [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer].
Herszényi L; Farinati F; Plebani M; István G; Sápi Z; Carraro P; De Paoli M; Naccarato R; Tulassay Z
Orv Hetil; 1999 Aug; 140(33):1833-6. PubMed ID: 10489782
[TBL] [Abstract][Full Text] [Related]
3. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
4. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
Herszényi L; Farinati F; Cardin R; István G; Molnár LD; Hritz I; De Paoli M; Plebani M; Tulassay Z
BMC Cancer; 2008 Jul; 8():194. PubMed ID: 18616803
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
Anticancer Res; 2000; 20(5C):3975-81. PubMed ID: 11268487
[TBL] [Abstract][Full Text] [Related]
8. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
9. [Expression of cathepsin B and its clinical importance in colorectal cancer].
Yu B; Li SY; An P; Zuo FY; Cai HY
Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Nov; 8(6):507-9. PubMed ID: 16299652
[TBL] [Abstract][Full Text] [Related]
10. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis.
Farinati F; Herszényi L; Plebani M; Carraro P; De Paoli M; Cardin R; Roveroni G; Rugge M; Nitti D; Grigioni WF; D'Errico A; Naccarato R
Carcinogenesis; 1996 Dec; 17(12):2581-7. PubMed ID: 9006092
[TBL] [Abstract][Full Text] [Related]
11. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
Yang SF; Hsieh YS; Lin CL; Hsu NY; Chiou HL; Chou FP; Chu SC
Clin Chim Acta; 2005 Apr; 354(1-2):91-9. PubMed ID: 15748604
[TBL] [Abstract][Full Text] [Related]
12. Cysteine and serine proteases in gastric cancer.
Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R
Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115
[TBL] [Abstract][Full Text] [Related]
13. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
14. uPA and PAI-1 in rectal cancer--relationship to radiotherapy and clinical outcome.
Angenete E; Langenskiöld M; Palmgren I; Falk P; Oresland T; Ivarsson ML
J Surg Res; 2009 May; 153(1):46-53. PubMed ID: 18533186
[TBL] [Abstract][Full Text] [Related]
15. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
16. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
[TBL] [Abstract][Full Text] [Related]
17. The role of cysteine and serine proteases in colorectal carcinoma.
Herszènyi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
Cancer; 1999 Oct; 86(7):1135-42. PubMed ID: 10506696
[TBL] [Abstract][Full Text] [Related]
18. Total and lipid-bound plasma sialic acid as diagnostic markers in colorectal cancer patients: correlation with cathepsin B expression in progression to Dukes stage.
Sebzda T; Saleh Y; Gburek J; Warwas M; Andrzejak R; Siewinski M; Rudnicki J
J Exp Ther Oncol; 2006; 5(3):223-9. PubMed ID: 16528972
[TBL] [Abstract][Full Text] [Related]
19. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
20. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
